JP2022515152A - Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 - Google Patents

Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 Download PDF

Info

Publication number
JP2022515152A
JP2022515152A JP2021535665A JP2021535665A JP2022515152A JP 2022515152 A JP2022515152 A JP 2022515152A JP 2021535665 A JP2021535665 A JP 2021535665A JP 2021535665 A JP2021535665 A JP 2021535665A JP 2022515152 A JP2022515152 A JP 2022515152A
Authority
JP
Japan
Prior art keywords
seq
set forth
chain variable
variable domain
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515152A5 (enExample
Inventor
チン，ホン
クワック，ラリー・ダブリュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2022515152A publication Critical patent/JP2022515152A/ja
Publication of JP2022515152A5 publication Critical patent/JP2022515152A5/ja
Priority to JP2024192700A priority Critical patent/JP2025032075A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021535665A 2018-12-19 2019-12-19 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 Pending JP2022515152A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192700A JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782317P 2018-12-19 2018-12-19
US62/782,317 2018-12-19
PCT/US2019/067563 WO2020132291A1 (en) 2018-12-19 2019-12-19 Baff-r bispecific t-cell engager antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192700A Division JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Publications (2)

Publication Number Publication Date
JP2022515152A true JP2022515152A (ja) 2022-02-17
JP2022515152A5 JP2022515152A5 (enExample) 2022-12-21

Family

ID=71098268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535665A Pending JP2022515152A (ja) 2018-12-19 2019-12-19 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Country Status (8)

Country Link
US (2) US20200199232A1 (enExample)
EP (1) EP3897720A4 (enExample)
JP (2) JP2022515152A (enExample)
KR (1) KR20210104816A (enExample)
CN (2) CN121405815A (enExample)
AU (1) AU2019404282A1 (enExample)
CA (1) CA3123599A1 (enExample)
WO (1) WO2020132291A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025162545A (ja) * 2024-04-15 2025-10-27 イーライ リリー アンド カンパニー Ｂａｆｆｒ×ｃｄ３二重特異性抗体及び使用方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4558522A1 (en) * 2022-07-19 2025-05-28 Novartis AG Treatment of aiha with baff or baff receptor inhibitory antibodies
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
AU2024227909A1 (en) * 2023-02-28 2025-08-14 Mayo Foundation For Medical Education And Research Molecules that bind to b-cell activating factor receptor polypeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522891A (ja) * 2014-07-31 2017-08-17 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 組織分布が向上した二重特異性単鎖抗体コンストラクト
WO2017214167A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
JP2018525005A (ja) * 2015-08-17 2018-09-06 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｂｃｍａ抗体、ｂｃｍａ及びｃｄ３に結合する二重特異性抗原結合分子、並びにそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CN104780940B (zh) * 2012-11-06 2017-11-07 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3916018A1 (en) * 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
IL313507A (en) * 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
EP4628094A3 (en) * 2016-06-06 2025-12-31 City of Hope BAFF-R ANTIBODIES AND THEIR USES
CN113874391B (zh) * 2019-02-20 2025-10-28 希望之城公司 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522891A (ja) * 2014-07-31 2017-08-17 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 組織分布が向上した二重特異性単鎖抗体コンストラクト
JP2018525005A (ja) * 2015-08-17 2018-09-06 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｂｃｍａ抗体、ｂｃｍａ及びｃｄ３に結合する二重特異性抗原結合分子、並びにそれらの使用
WO2017214167A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRAID F. ET AL.: "Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 m", BLOOD, vol. 129, JPN6023046872, 2017, pages 100 - 104, ISSN: 0005360587 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025162545A (ja) * 2024-04-15 2025-10-27 イーライ リリー アンド カンパニー Ｂａｆｆｒ×ｃｄ３二重特異性抗体及び使用方法

Also Published As

Publication number Publication date
US20220056132A1 (en) 2022-02-24
US20200199232A1 (en) 2020-06-25
CN113412124A (zh) 2021-09-17
AU2019404282A1 (en) 2021-07-01
JP2025032075A (ja) 2025-03-11
EP3897720A4 (en) 2022-12-07
WO2020132291A1 (en) 2020-06-25
EP3897720A1 (en) 2021-10-27
CN121405815A (zh) 2026-01-27
CA3123599A1 (en) 2020-06-25
KR20210104816A (ko) 2021-08-25

Similar Documents

Publication Publication Date Title
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
JP2022515152A (ja) Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP7788118B2 (ja) ヒトネクチン－２に特異的な抗体
RS64588B1 (sr) Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera
CN110753756A (zh) 免疫调节性多核苷酸及其应用
JP7159187B2 (ja) セマフォリン－４ｄ抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法
KR20210104166A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
JP7734386B2 (ja) 医薬組成物、その製造方法及び用途
TW202342507A (zh) 抗ｓｔｅａｐ２嵌合抗原受體及其用途
JP7801225B2 (ja) 抗ｔｎｆｒ２抗体及びその使用
WO2023023677A1 (en) Strategy for highly superior dr5 activation including in tumors and cancers
US20230391881A1 (en) Compositions and methods for overcoming dr5-induced immune evasion by solid tumors
TW202328176A (zh) 抗-sars-cov-2抗體組成物及其用途
US20240382592A1 (en) Methods for the treatment of anaplastic large cell lymphoma
US20240299449A1 (en) Anti-cd72 nanobodies for immunotherapy
JP2025508690A (ja) 癌免疫療法のためのａｒｔ１の標的化
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP2025540215A (ja) Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
HK40113788A (zh) 抗cd39抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702